JP2020512336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512336A5 JP2020512336A5 JP2019552871A JP2019552871A JP2020512336A5 JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5 JP 2019552871 A JP2019552871 A JP 2019552871A JP 2019552871 A JP2019552871 A JP 2019552871A JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- compound
- zero
- use according
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C(*)(*)NC)=O Chemical compound CC(C(*)(*)NC)=O 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034511A JP7795489B2 (ja) | 2017-03-31 | 2023-03-07 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901180A AU2017901180A0 (en) | 2017-03-31 | Treatment of respiratory infection | |
| AU2017901180 | 2017-03-31 | ||
| AU2017905128A AU2017905128A0 (en) | 2017-12-21 | Optimised compounds | |
| AU2017905124A AU2017905124A0 (en) | 2017-12-21 | Treatment of respiratory infection (2) | |
| AU2017905124 | 2017-12-21 | ||
| AU2017905128 | 2017-12-21 | ||
| AU2018900409 | 2018-02-09 | ||
| AU2018900409A AU2018900409A0 (en) | 2018-02-09 | Treatment of respiratory infection (3) | |
| PCT/AU2018/050295 WO2018176099A1 (en) | 2017-03-31 | 2018-03-29 | Treatment of respiratory infection with a tlr2 agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034511A Division JP7795489B2 (ja) | 2017-03-31 | 2023-03-07 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512336A JP2020512336A (ja) | 2020-04-23 |
| JP2020512336A5 true JP2020512336A5 (https=) | 2021-04-08 |
| JP7719590B2 JP7719590B2 (ja) | 2025-08-06 |
Family
ID=63673872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552871A Active JP7719590B2 (ja) | 2017-03-31 | 2018-03-29 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
| JP2023034511A Active JP7795489B2 (ja) | 2017-03-31 | 2023-03-07 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034511A Active JP7795489B2 (ja) | 2017-03-31 | 2023-03-07 | Ｔｌｒアゴニストによる呼吸器感染症の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200147028A1 (https=) |
| EP (1) | EP3600374B1 (https=) |
| JP (2) | JP7719590B2 (https=) |
| CN (2) | CN110461351B (https=) |
| AU (1) | AU2018241248B2 (https=) |
| ES (1) | ES2979287T3 (https=) |
| PL (1) | PL3600374T3 (https=) |
| WO (1) | WO2018176099A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2618842B1 (en) | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| AU2018391325B2 (en) * | 2017-12-21 | 2024-07-11 | Axelia Oncology Pty Ltd | Optimised compounds |
| WO2019119069A1 (en) * | 2017-12-21 | 2019-06-27 | Ena Therapeutics Pty Ltd | Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent |
| MX2021015961A (es) * | 2019-06-26 | 2022-03-22 | Ena Respiratory Pty Ltd | Moleculas novedosas. |
| US20220347146A1 (en) * | 2019-09-04 | 2022-11-03 | Axelia Oncology Pty Ltd | Cancer treatment |
| AU2020340468A1 (en) * | 2019-09-04 | 2022-03-24 | Axelia Oncology Pty Ltd | Cancer immunotherapy |
| WO2021231499A2 (en) * | 2020-05-11 | 2021-11-18 | Revir, Inc. | Compositions and methods for treating viral infections |
| WO2021237291A1 (en) * | 2020-05-26 | 2021-12-02 | Axelia Oncology Pty Ltd | Treatment of coronavirus |
| JP7744936B2 (ja) * | 2020-06-26 | 2025-09-26 | イーナ レスパラトリー ピーティーワイ リミテッド | 分岐脂質化合物 |
| EP4395761A4 (en) * | 2021-08-31 | 2025-10-01 | Ena Respiratory Pty Ltd | ALLERGY TREATMENT |
| WO2023028661A1 (en) * | 2021-09-02 | 2023-03-09 | Ena Respiratory Pty Ltd | Formulation |
| CN114539356B (zh) * | 2022-02-21 | 2023-06-09 | 中国人民解放军陆军军医大学 | 一种脂肽及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4119856A1 (de) | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| AU2003223718B2 (en) * | 2002-04-25 | 2007-08-16 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
| EP1755635A4 (en) * | 2004-05-27 | 2011-04-06 | Novozymes Biopharma Au Ltd | TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE |
| WO2009137103A2 (en) * | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
| JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| EP2618842B1 (en) * | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| CN113876945A (zh) * | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| US20170274068A1 (en) * | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
-
2018
- 2018-03-29 CN CN201880020768.1A patent/CN110461351B/zh active Active
- 2018-03-29 WO PCT/AU2018/050295 patent/WO2018176099A1/en not_active Ceased
- 2018-03-29 ES ES18774987T patent/ES2979287T3/es active Active
- 2018-03-29 AU AU2018241248A patent/AU2018241248B2/en active Active
- 2018-03-29 JP JP2019552871A patent/JP7719590B2/ja active Active
- 2018-03-29 CN CN202410307367.1A patent/CN118161614A/zh active Pending
- 2018-03-29 US US16/495,829 patent/US20200147028A1/en active Pending
- 2018-03-29 PL PL18774987.4T patent/PL3600374T3/pl unknown
- 2018-03-29 EP EP18774987.4A patent/EP3600374B1/en active Active
-
2023
- 2023-03-07 JP JP2023034511A patent/JP7795489B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512336A5 (https=) | ||
| JP7795489B2 (ja) | Ｔｌｒアゴニストによる呼吸器感染症の治療 | |
| JP2023081969A5 (https=) | ||
| JP6911044B2 (ja) | 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ | |
| JP2010502738A (ja) | ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法 | |
| CN108350022A (zh) | 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法 | |
| US10258634B2 (en) | Ciclesonide for the treatment of airway disease in horses | |
| KR20200101428A (ko) | 최적화된 화합물 | |
| AU2018370019A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
| CN113966237A (zh) | pHLIP®介导的皮质类固醇靶向病变组织 | |
| CN106488770A (zh) | 用于治疗copd的福莫特罗和布地奈德的组合 | |
| JP4959919B2 (ja) | 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 | |
| RU2010137337A (ru) | Способы и композиции для лечения респираторных заболеваний | |
| JP2007512223A5 (https=) | ||
| JP7254130B2 (ja) | 結晶多形および医薬組成物 | |
| US20160331839A1 (en) | Method for increasing the bioavailability of inhaled compounds | |
| CN114144195A (zh) | 血管活性肠肽(vip)用于治疗药源性肺炎的用途 | |
| RU2013116520A (ru) | Гиперсульфатированные дисахариды для лечения нарушений, связанных с эластазой | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| RU2504382C1 (ru) | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения | |
| RU2494730C1 (ru) | Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения | |
| EP4392052A1 (en) | Compositions and methods for treating and preventing lung disease | |
| WO2023028491A1 (en) | Compositions and methods for treating and preventing lung disease | |
| HK1246147B (zh) | 聚乙二醇基肾上腺髓质素前药及其用途 | |
| KR20060118509A (ko) | 신규 화합물 |